TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately

Clinical Trial Summary

The primary objective of the study is to confirm that at least 1 or more doses of telotristat etiprate compared to placebo is effective in reducing the number of daily bowel movements (BMs) from baseline averaged over the 12-week double-blind portion (Treatment Period) of the trial in patients not adequately controlled by current SSA therapy.

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04993261` - An Investigational Scan (Dual Energy CT) in Detecting Gastrointestinal Carcinoid Tumors	Early Phase 1
Not yet recruiting	`NCT04039516` - Carcinoid Heart Disease and Peptide Receptor Radiotargetted Therapy	Phase 2
Completed	`NCT01234168` - A Study to Assess Neuroendocrine Tumour (NET) Patients Currently Treated by Somatuline Autogel for History of Carcinoid Syndrome Associated With Episodes of Diarrhea
Terminated	`NCT04073017` - Enterade in Carcinoid/Non-Carcinoid Syndrome Neuroendocrine Tumor Patients With Quality of Life Limiting Bowel Frequency	N/A
Recruiting	`NCT05756608` - Fibrosis in Chronic and Delayed Myocardial Infarction
Completed	`NCT00774930` - An Efficacy and Safety Study of Somatuline Depot (Lanreotide) Injection to Treat Carcinoid Syndrome	Phase 3
Withdrawn	`NCT04713202` - Prospective Assessment of Patients With Neuroendocrine Tumors and Current or Prior History of Carcinoid Syndrome or Diarrhea Undergoing Peptide Receptor Radionuclide Therapy With or Without Telotristat Ethyl	Phase 2
Completed	`NCT00853047` - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome Not Managed by Stable-Dose Octreotide Therapy	Phase 2
Completed	`NCT02063659` - Telotristat Etiprate for Carcinoid Syndrome Therapy	Phase 3
Withdrawn	`NCT04776876` - Retifanlimab (INCMGA00012) and Telotristat Ethyl for the Treatment of Advanced Neuroendocrine Tumors and Carcinoid Syndrome	Phase 2
Completed	`NCT03223428` - Real-world Evidence Study EvaLuating PAtient-Reported Outcomes With XERMELO
Recruiting	`NCT03453489` - AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm	Phase 2
Active, not recruiting	`NCT05361668` - Study to Evaluate the Safety, PK, and Dose Response of Paltusotine in Subjects With Carcinoid Syndrome	Phase 2
Completed	`NCT01104415` - Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome	Phase 2
Withdrawn	`NCT01172717` - Study of Panitumumab in the Treatment of Carcinoid Syndrome	Phase 2
Terminated	`NCT00884715` - Pharmacokinetics, Efficacy and Safety of an Octreotide Implant in Patients With Carcinoid Syndrome	Phase 1/Phase 2
Completed	`NCT01430871` - Effects of Serotonin Excess on Bone in Carcinoid Syndrome	N/A
Completed	`NCT02026063` - Telotristat Etiprate - Expanded Treatment for Patients With Carcinoid Syndrome Symptoms	Phase 3
Terminated	`NCT01018953` - Study to Assess the Efficacy and Safety of Different Doses of BIM 23A760 in Patients With Carcinoid Syndrome	Phase 2
Terminated	`NCT04140409` - Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation	Phase 4

NCT number	NCT01677910
Study type	Interventional
Source	Lexicon Pharmaceuticals
Contact
Status	Completed
Phase	Phase 3
Start date	January 8, 2013
Completion date	March 21, 2016

TELESTAR (Telotristat Etiprate for Somatostatin Analogue Not Adequately Controlled Carcinoid Syndrome)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms